New Player In The Fight Against Resistant Fungal Infections In Phase 3 Trial
Rezafungin is a novel molecule in the echinocandin class of antifungals, which its developer Cidara believes will be an improvement among current fungal infections treatments. Rezafungin is being developed as a first-line treatment of candidemia and invasive candidiasis.
Brooklyn boy with rare blood disease to speak at awareness event on Feb. 29
Zach, his family and other people suffering from rare diseases will be guests of honor at an event commemorating Rare Disease Day on Leap Day – the rarest day of the year – at Carnegie Hall. Rocket Pharmaceuticals, Inc., a company that researches genetic solutions for diseases like Zach’s, is organizing the event for the second year.
Edmonton Health Matters: Experimental therapy helps man see
An Alberta man with severe vision loss can now see things he hasn’t been able to since he was a child. As Su-Ling Goh reports, the RNA therapy that helped patient Dean Scott is being called a “game-changer” for various types of blindness.
Natural Killer Cells Plus Immunotherapy for Triple-Negative Breast Cancer
Q: Your experimental protocol was given as third-line treatment, is that correct? Most patients were on their third line of treatment, but inclusion criteria were beyond first-line standard of care.
Ingestible Diagnostics: Technical Challenges, Regulatory Considerations, and Reimbursement
A number of ingestible technologies have been developed for the diagnosis of gastrointestinal (GI) diseases, including the use of conventional tools, such as endoscopy, radiological imaging, or biochemical tests. Ingestible diagnostics are particularly useful for the exploration of the small bowelii, since gastroscopy can only reach a limited area of the small intestine and alternative methods with further reach, such as balloon enteroscopy, require specific expertise and infrastructure.
After digging through discards, biotech startup is making a $45M bet it can fix a failed cancer therapy
“Their Phase I data was stellar, great Phase I, and then they had this Phase II that failed primarily because they added the wrong drug,” Asher Nathan, CEO and co-founder of NeoTX, told Endpoints News as he unveils $45 million in new financing.
The Process Behind The Potential: Cue Biopharma’s Therapy For HPV16-Related Malignancies
A look into Cue Biopharma’s engineering-centric approach to in vivo tumor antigen specific T cell activation. Late last month, Cue Biopharma shared preclinical and translational data supporting the therapeutic potential of CUE-101 in HPV16-related malignancies.
Tackling unmet needs: new compounds in development for non-functioning pituitary adenomas and rare endocrine diseases
In today’s podcast, we highlight a new company dedicated to the rare endocrine disease world. Tiburio Therapeutics is working on two exciting compounds for the treatment of Non-functioning Pituitary Adenomas and rare endocrine disorders.
